Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...